Scientific publications

Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network

Ludwig H (1), Delforge M (2), Facon T (3), Einsele H (4), Gay F (5), Moreau P (6), Avet-Loiseau H (7), Boccadoro M (8), Hajek R (9), Mohty M (10), Cavo M (11), Dimopoulos MA (12), San-Miguel JF (13), Terpos E (12), Zweegman S (14), Garderet L (10), Mateos MV (15), Cook G (16), Leleu X (17), Goldschmidt H (18), Jackson G (19), Kaiser M (20), Weisel K (21), van de Donk NWCJ (14), Waage A (22), Beksac M (23), Mellqvist UH  (24), Engelhardt M (25), Caers J (26), Driessen C (27), Bladé J (28), Sonneveld P (29).

(1) Wilhelminen Cancer Research Institute, Vienna, Austria.
(2) Department of Hematology, University Hospital Leuven, Catholic University Leuven, Leuven, Belgium.
(3) Department of Hematology, Lille University Hospital, Lille, France.
(4) Department of Internal Medicine II, University Hospital of Wuerzburg, Wuerzburg, Germany.
(5) Myeloma Unit, Division of Hematology, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, University of Torino, Torino, Italy.
(6) Department of Hematology, University Hospital, University of Nantes, Nantes, France.
(7) Centre de Recherches en Cancerologie de Toulouse CRCT, Institut National de la Sante et de la Recherche Medicale, Université Toulouse, Toulouse, France.
(8) Division of Hematology, Citta della Salute e della Scienza, University of Torino, Torino, Italy.
(9) Faculty of Medicine, University Hospital Ostrava, University of Ostrava, Ostrava, Czech Republic.
(10) Department of Haematology, Saint Antoine Hospital, University Pierre and Marie Curie, and INSERM UMRs 938, Paris, France.
(11) A 'Seràgnoli' Institute of Hematology, Bologna University School of Medicine, Bologna, Italy.
(12) Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.
(13) Department of Hematology, Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), IDISNA, CIBERONC, Pamplona, Spain.
(14) Department of Hematology, VU University Medical Center, Amsterdam, The Netherlands.
(15) Hospital Universitario de Salamanca, Instituto Biosanitario de Salamanca (IBSAL), Salamanca, Spain.
(16) Leeds Institute of Cancer and Pathology, University of Leeds, Leeds, UK.
(17) Service d'Hématologie et Thérapie Cellulaire, PRC, and Inserm CIC1402, Hospital de la Miléterie, Poitiers, France.
(18) National Center for Tumor Diseases, Heidelberg Medical University, Heidelberg, Germany.
(19) Department of Hematology, Newcastle University, Newcastle, UK.
(20) Myeloma Group, The Institute of Cancer Research ICR, London, UK.
(21) Department of Hematology and Oncology, University of Tuebingen, Tuebingen, Germany.
(22) Department of Hematology, St. Olavs Hospital, and IKOM, NTNU, Trondheim, Norway.
(23) Department of Medicine, Ankara University, Ankara, Turkey.
(24) Department of Hematology, Sahlgrenska Hospital, Gothenburg, Sweden.
(25) Department of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany.
(26) Department of Hematology, University Hospital of Liège, Liège, Belgium.
(27) Department of Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland.
(28) Department of Hematology, Amyloidosis and Myeloma Unit, Hospital Clínic de Barcelona, Spain.
(29) Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.

Magazine: Leukemia

Date: May 2, 2018

Hematología y Hemoterapia [SP]

ABSTRACT

During the last few years, several new drugs have been introduced for treatment of patients with multiple myeloma, which have significantly improved the treatment outcome.

All of these novel substances differ at least in part in their mode of action from similar drugs of the same drug class, or are representatives of new drug classes, and as such present with very specific side effect profiles.

In this review, we summarize these adverse events, provide information on their prevention, and give practical guidance for monitoring of patients and for management of adverse events.

CITATION  Leukemia. 2018 May 2. doi: 10.1038/s41375-018-0040-1

you maybe interested

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra